T-THERAPEUTICS
LIVE

Serial Number

98081081

Owner

T-Therapeutics Limited

Attorney

Stacy J. Grossman

Filing Date

Jul 12, 2023

Add to watchlist:

No watchlists yet
View on USPTO

T-THERAPEUTICS Trademark

Serial Number: 98081081 • Registration: 8330457

T-THERAPEUTICS is a trademark filed by T-Therapeutics Limited on July 12, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

T-Therapeutics Limited (7 trademarks)

Abington Hall, Granta Park
Cambridge CB216AL , GB

Entity Type: 99

Trademark Details

Filing Date

July 12, 2023

Registration Date

July 7, 2026

Published for Opposition

May 19, 2026

Goods & Services

Pharmaceutical preparations for the protection from and prevention of viral and bacterial infections, cancer, inflammation, autoimmune diseases and infectious diseases; pharmaceutical preparations, in particular, chemical and biological preparations for medical purposes, namely, for the protection from and prevention of viral and bacterial infections, cancer, inflammation, autoimmune diseases and infectious diseases; chemical preparations for use in DNA analysis for medical purposes; DNA synthesis inhibitors for medical purposes, namely, pharmaceutical preparations for the protection from and prevention of viral and bacterial infections, cancer, inflammation, autoimmune diseases and infectious diseases; biological preparations for the treatment of cancer; biological preparations for the treatment of viral and bacterial infections; biological preparations for the treatment of autoimmune diseases; biological preparations for medical use for the treatment of viral and bacterial infections, cancer, inflammation, autoimmune diseases and infectious diseases; immunotherapeutic drugs namely, pharmaceutical preparations for the protection from and prevention of viral and bacterial infections, cancer, inflammation, autoimmune diseases and infectious diseases; reagents for medical use; diagnostic preparations for medical use; diagnostic reagents for medical use; preparations for detecting genetic predispositions for medical purposes; excluding preparations for RNA-based gene silencing

Downloadable computer software for use in collecting, analyzing and organizing data in the field of pharmaceuticals, biopharmaceutical drug development and genome engineering; downloadable computer software for use in collecting, analyzing and organizing data in the field of scientific and pharmaceutical research and development; downloadable software for scientific modelling of pharmaceuticals in the field of scientific and pharmaceutical research and development; downloadable software for pharmaceutical modelling; downloadable software for research and development in the nature of collecting, analyzing and organizing data in the field of antibodies; devices for analyzing genome information, namely, laboratory devices for detecting genetic sequences; downloadable software for performing gene sequencing research and visualization, namely, scientific analysis of genetic sequences; downloadable software for the managing, analysis, and visualization of biological data; excluding software and devices for RNA-based gene silencing and hepatocyte-specific computational biology

Medical services; diagnostic and prognostic medical services; veterinary services; medical analysis services relating to the treatment of persons; pharmaceutical advice; medical and health care services relating to DNA, genetics, and genetic pathogen testing for diagnostic or treatment purposes; medical screening and assaying in the nature of medical laboratory analysis services relating to the treatment of persons; DNA screening for medical purposes; DNA analysis services in the field of DNA sequencing for diagnostic and treatment purposes provided by medical laboratories

Scientific and technological services, namely, scientific research and development in the field of pharmaceuticals for genome engineering and biopharmaceutical drug development for protection from infections, cancer, disease or inflammation; technical research in the field of pharmaceutical studies; design and development of computer hardware and software; platform as a service (PAAS) featuring computer software platforms for use in database management in the field of pharmaceuticals, biopharmaceutical drug development and genome engineering; platform as a service (PAAS) featuring DNA analysis software platforms; software as a service (SAAS) services featuring software for use in database management in the field of pharmaceuticals, biopharmaceutical drug development and genome engineering; software as a service (SAAS) services featuring DNA analysis software; provision of online non-downloadable software for the management, visualization and analysis of biological data for the purposes of biomolecular research and the design and engineering of biomolecular products; DNA analysis services in the field of DNA sequencing for scientific research; provision of a web hosting platform for the analysis of DNA sequencing data for scientific research purposes and diagnostic and treatment purposes; excluding services related to RNA-based gene silencing and hepatocyte-specific computational biology

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 7, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 7, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 19, 2026 NPUB
PUBLISHED FOR OPPOSITION
May 19, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 13, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 21, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 21, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 21, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 21, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 21, 2026 CNEA
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jan 1, 2026 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jun 30, 2025 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jun 20, 2025 RCSC
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 28, 2025 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 28, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 28, 2025 COAR
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 16, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Dec 16, 2024 GNSL
SUSPENSION LETTER WRITTEN
Dec 16, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 7, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 7, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 7, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Oct 9, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Oct 9, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 10, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jul 10, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jul 10, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 11, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 11, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 11, 2024 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 31, 2024 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 31, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 31, 2024 COAR
CORRESPONDENCE E-MAILED
Mar 27, 2024 GRML
NON-FINAL ACTION WRITTEN
Mar 27, 2024 CNRT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 27, 2024 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 27, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 27, 2024 COAR
ASSIGNED TO EXAMINER
Mar 20, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 10, 2023 NWOS
NEW APPLICATION ENTERED
Jul 15, 2023 NWAP